← Browse by Condition
Medical Condition

dry age related macular degeneration

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 3

ClinicalMetric tracks all active clinical trials for dry age related macular degeneration sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — dry age related macular degeneration Clinical Trials

How many clinical trials are currently recruiting for dry age related macular degeneration?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for dry age related macular degeneration, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for dry age related macular degeneration?
dry age related macular degeneration research spans Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a dry age related macular degeneration clinical trial?
Eligibility criteria for dry age related macular degeneration trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 3
1
Top Sponsors
LumiThera, Inc. 1 trial
Ocugen 1 trial
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1 trial
Carl Zeiss Meditec-Dublin CoCe 1 trial

Recruiting Clinical Trials

NCT06351605
Recruiting
A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (GLOBALIGHT)
Enrollment
500 pts
Location
United States, Norwa...
Sponsor
LumiThera, Inc.
View Trial →
NCT07770828 Phase 3
Recruiting
Phase 3 Study to Assess Efficacy, Safety & Tolerability of OCU410 For Geographic Atrophy Secondary to Dry AMD
Enrollment
237 pts
Location
United States
Sponsor
Ocugen
View Trial →
NCT06536062
Recruiting
Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma.
Enrollment
36 pts
Location
Italy
Sponsor
Fondazione Policlinico Univers...
View Trial →
NCT07680244
Recruiting
(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000
Enrollment
400 pts
Location
United States
Sponsor
Carl Zeiss Meditec-Dublin CoCe
View Trial →

Related Conditions

epiretinal membrane (1) macular abnormalities (1) retina disease (1) vitreoretinal abnormality (1) intraretinal hyporeflective space (1) subretinal hyporeflective space (1) is os ellipsoid zone disruption (1) retinal pigment epithelium rpe elevation (1) retinal pigment epithelium rpe atrophy (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology